¼¼°èÀÇ Æ®·Òºó ½ÃÀå : À¯Çü, ÇüÅÂ, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)
Thrombin Market by Type (Bovine Thrombin, Human Plasma Thrombin, Recombinant Thrombin), Form (Liquid, Powder), End-User - Global Forecast 2025-2030
»óǰÄÚµå : 1598429
¸®¼­Ä¡»ç : 360iResearch Private Limited
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 193 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,939 £Ü 5,637,000
PDF, Excel & 1 Year Online Access (Single User License) help
PDF ¹× Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 4,249 £Ü 6,081,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿Àϱâ¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 5,759 £Ü 8,242,000
PDF, Excel & 1 Year Online Access (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ Áö¿ª »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 6,969 £Ü 9,974,000
PDF, Excel & 1 Year Online Access (Enterprise User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Æ®·Òºó ½ÃÀåÀº 2023³â¿¡ 6¾ï 4,896¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 6¾ï 8,505¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 6.14%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 9¾ï 8,529¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»ó ¿¹ÃøµË´Ï´Ù.

Ç÷¾× ÀÀ°í¿¡ Áß¿äÇÑ È¿¼ÒÀÎ Æ®·ÒºóÀº ÁöÇ÷À» µ½±â À§ÇØ ÀÇ·á Ä¡·á¿¡ ³Î¸® »ç¿ëµË´Ï´Ù. Æ®·ÒºóÀÇ ÀÀ¿ë ¹üÀ§´Â º´¿ø¿¡¼­ Àü¹® ¼ö¼ú¼¾ÅÍ¿¡ À̸£±â±îÁö ´Ù¾çÇÑ ÃÖÁ¾ ¿ëµµ ¹× ¹ÙÀÌ¿À ÀǾàǰ ¿¬±¸¿¡ÀÇ Àü°³°¡ »õ·Î¿î ÀϸéÀ» ´õÇϰí ÀÖ½À´Ï´Ù. Æ®·Òºó ½ÃÀåÀº ¼¼°è ¼ö¼ú Áõ°¡, ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡, Æ®·ÒºóÀÇ È¿´ÉÀ» ³ôÀÌ´Â »ý¸í °øÇÐÀÇ Áøº¸¿Í °°Àº ¼ºÀå ¿äÀÎÀÇ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. Æ®·Òºó ¹× ±âŸ »ý¹°°øÇÐÀû °³·®ÇüÀÇ °³¹ß¿¡ »õ·Î¿î ±âȸ°¡ ÀÖ¾î, ±âÁ¸ ÇüÅÂ¿Í °ü·ÃµÈ ¾Ë·¹¸£°Õ ¹× º´¿øÃ¼ º¯¼ÓÀÇ °úÁ¦¸¦ ÇØ°áÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 6¾ï 4,896¸¸ ´Þ·¯
¿¹Ãø³â(2024) 6¾ï 8,505¸¸ ´Þ·¯
¿¹Ãø³â(2030) 9¾ï 8,529¸¸ ´Þ·¯
CAGR(%) 6.14%

±×·¯³ª ½ÃÀåÀº ÇѰ迡 Á÷¸éÇϰí ÀÖÀ¸¸ç, ƯÈ÷ Á¦Á¶ ºñ¿ëÀÇ ³ôÀÌ¿Í ´ëü ÀÀ°íÁ¦¿ÍÀÇ °æÀïÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù. Áö¿¬ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀϺΠȯÀÚÀÇ ºÎÀÛ¿ë¿¡ ´ëÇÑ ¿ì·Áµµ ÀÖÀ¸¸ç, º¸´Ù ±¤¹üÀ§ÇÑ Àû¿ëÀÌ Á¦ÇÑ µÉ ¼ö ÀÖ½À´Ï´Ù ÀÌ·¯ÇÑ °úÁ¦¿¡µµ ºÒ±¸ÇÏ°í Æ®·ÒºóÀÇ »ýüÀÌ¿ë·ü°ú ƯÀ̼ºÀ» ³ôÀ̱â À§ÇÑ ºÐÀÚ º¯°æ¿¡ ÃÊÁ¡À» ¸ÂÃß¸é ±â¼ú Çõ½ÅÀÌ »ç¾÷ ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾ÈÁ¤ÀûÀÎ Á¦ÇüÀÇ Æ®·Òºó ¾Æ³¯·Î±×¸¦ °³¹ßÇÏ´Â ¿¬±¸´Â »õ·Î¿î ½ÃÀåÀ» °³Ã´ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Æ®·Òºó ½ÃÀåÀÇ ¿ªµ¿Àû ÀÎ ¼º°ÝÀº ¼º¼÷ÇÑ ¾ÖÇø®ÄÉÀ̼ǰú »õ·Î¿î ±â¼ú Áøº¸ÀÇ À¶ÇÕÀ» ¹Ý¿µÇÕ´Ï´Ù. ½ÃÀå ±âȸ¸¦ Ȱ¿ëÇϱâ À§ÇØ ±â¾÷Àº »ý¸í °øÇÐ ±â¾÷ ¹× ¿¬±¸ ±â°ü°úÀÇ Àü·«Àû ÆÄÆ®³Ê½Ê ±â¾÷Àº ±ÔÁ¦ ±âÁØ¿¡ µû¶ó °øµ¿ Çõ½ÅÀ» ÃßÁøÇØ¾ß ÇÕ´Ï´Ù. ¼±°ß¼ºÀ» °áÇÕÇÏ¸é °úÁ¦¸¦ È¿°úÀûÀ¸·Î ÁÙÀ̸鼭 ÀáÀç·ÂÀ» ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â Æ®·Òºó ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Æ®·Òºó ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿Àû ÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ±×¸®°í »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñ ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡ ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Porter's Five Forces: Æ®·Òºó ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â Æ®·Òºó ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ´ç½ÅÀº ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Æ®·Òºó ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Æ®·Òºó ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇϴµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡ µÇ¾ú½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : Æ®·Òºó ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

Æ®·Òºó ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õ´Â °æÀïÀÌ Ä¡¿­ÇØÁö¸é¼­ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» Çϱâ À§ÇØ ÇÊ¿äÇÑ Áö°ß À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : Æ®·Òºó ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Æ®·Òºó ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÎ¹®È­Çϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : Æ®·Òºó ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸³´Ï´Ù.

Æ®·Òºó ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ Á¸À縦 °­È­ÇÏ·Á´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ´É·Â ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

Á¦6Àå Æ®·Òºó ½ÃÀå : À¯Çüº°

Á¦7Àå Æ®·Òºó ½ÃÀå : Çüź°

Á¦8Àå Æ®·Òºó ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦9Àå ¾Æ¸Þ¸®Ä« Æ®·Òºó ½ÃÀå

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Æ®·Òºó ½ÃÀå

Á¦11Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Æ®·Òºó ½ÃÀå

Á¦12Àå °æÀï ±¸µµ

±â¾÷ ¸ñ·Ï

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Thrombin Market was valued at USD 648.96 million in 2023, expected to reach USD 685.05 million in 2024, and is projected to grow at a CAGR of 6.14%, to USD 985.29 million by 2030.

Thrombin, a crucial enzyme for blood coagulation, is extensively utilized in medical procedures to aid in hemostasis. Its primary necessity stems from its role in controlling bleeding, making it indispensable in surgical settings and wound management. The application scope for thrombin spans across various end-uses, from hospitals to specialized surgical centers, and its deployment in biopharmaceutical research adds another dimension. The market for thrombin is influenced by growth factors such as an increase in surgical procedures globally, the rising prevalence of cardiovascular diseases, and advancements in biotechnology that enhance thrombin's efficacy. Emerging opportunities lie in the development of recombinant thrombin and other bioengineered variants, which promise to address allergens and pathogen-transmission challenges associated with traditional forms.

KEY MARKET STATISTICS
Base Year [2023] USD 648.96 million
Estimated Year [2024] USD 685.05 million
Forecast Year [2030] USD 985.29 million
CAGR (%) 6.14%

However, the market faces limitations, notably the high cost of thrombin production and competition from alternative clotting agents. Regulatory hurdles and stringent safety requirements also pose significant challenges, potentially delaying product approvals and market expansion. There are also concerns about adverse reactions in a subset of patients that can limit its broader application. Despite these challenges, innovation can drive business growth by focusing on molecular modifications to enhance thrombin bioavailability and specificity. Moreover, research into developing thrombin analogs with longer shelf life and stable formulations could open new markets.

The dynamic nature of the thrombin market reflects a blend of matured applications and nascent technological advancements. Recombinant DNA technology represents a promising area for business development, providing a safer and more controlled thrombin variant. To capitalize on market opportunities, businesses should invest in strategic partnerships with biotechnology firms and research institutions, promoting collaborative innovation that aligns with regulatory standards. By understanding these nuances, businesses can better navigate the thrombin market landscape, combining innovative research with strategic foresight to tap into its vast potential while mitigating challenges effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Thrombin Market

The Thrombin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Porter's Five Forces: A Strategic Tool for Navigating the Thrombin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Thrombin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Thrombin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Thrombin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Thrombin Market

A detailed market share analysis in the Thrombin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Thrombin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Thrombin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Thrombin Market

A strategic analysis of the Thrombin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Thrombin Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Baxter International Inc., Bayer AG, BIOFAC A/S, BioMedica Diagnostics Inc., BioPharm Laboratories, LLC, Cayman Chemical, DiaPharma Group, Inc., Grifols, S.A., Johnson & Johnson Services, Inc., Medix Biochemica USA Inc., Merck KGaA, Mochida Pharmaceutical Co., Ltd., MyBioSource, Octapharma AG, Pfizer, Inc., Prolytix, Prospec-Tany Technogene Ltd., Proteintech Group, Inc., Regen Lab SA, Rocky Mountain Biologicals, LLC., Shanghai RAAS blood products co., Ltd, Takeda Pharmaceutical Company Limited., Teleflex Incorporated., Thermo Fisher Scientific Inc., and XD BIOCHEMS LIMITED.

Market Segmentation & Coverage

This research report categorizes the Thrombin Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Thrombin Market, by Type

7. Thrombin Market, by Form

8. Thrombin Market, by End-User

9. Americas Thrombin Market

10. Asia-Pacific Thrombin Market

11. Europe, Middle East & Africa Thrombin Market

12. Competitive Landscape

Companies Mentioned

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â